Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;19(6):690-696.
doi: 10.1111/ajco.13932. Epub 2023 Mar 13.

Radioimmunotherapy with 131 I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Yoon Jung Jang  1 , Sang Moo Lim  2 , Inki Lee  2 , Byung Hyun Byun  2 , Ilhan Lim  2 , Byung Il Kim  2 , Chang Woon Choi  2 , Seung-Sook Lee  3 , Cheolwon Suh  4 , Dok Hyun Yoon  4 , Inho Kim  5 , Seung-Hyun Nam  6 , Mark Hong Lee  7 , Jong Ho Won  8 , Jee Hyun Kong  9 , Seong Hyun Jeong  10 , Suk Joong Oh  11 , Keon Woo Park  12 , Jae Joon Han  13 , Moo-Kon Song  14 , Sung Hyun Yang  1 , Im Il Na  1 , Hyo-Rak Lee  1 , Dong-Yeop Shin  1   5 , Hye Jin Kang  1
Affiliations

Radioimmunotherapy with 131 I-rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Yoon Jung Jang et al. Asia Pac J Clin Oncol. 2023 Dec.

Abstract

Aim: This study aimed to evaluate the safety and efficacy of 131 I-rituximab in patients with relapsed or refractory follicular or mantle cell lymphoma.

Methods: Twenty-four patients with relapsed or refractory follicular or mantle cell lymphoma were administered unlabeled rituximab (70 mg) immediately before receiving a therapeutic dose of 131 I-rituximab. Contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography was used a month later to assess tumor response.

Results: This study enrolled 24 patients between June 2012 and 2022. Depending on how they responded to radioimmunotherapy (RIT), 131 I-rituximab was administered one to five times. Of the 24 patients, 9 achieved complete response after RIT and 8 achieved partial response. The median progression-free and overall survival was 5.9 and 37.9 months, respectively. During the follow-up period of 64.2 months, three patients were diagnosed with a secondary malignancy. Among treatment-related adverse events, hematologic toxicities were common, and grade 3-4 thrombocytopenia and neutropenia were reported in 66.6% of cases.

Conclusion: 131 I-rituximab has an effective and favorable safety profile in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. This suggests that RIT may also be considered a treatment option for patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.

Keywords: 131I-rituximab; follicular lymphoma; mantle cell lymphoma; phase II trial; radioimmunotherapy.

PubMed Disclaimer

References

REFERENCES

    1. Chatal JF, Mahé M. Therapeutic use of radiolabelled antibodies. In: Murray IPC, Ell PJ, eds. Nuclear Medicine in Clinical Diagnosis and Treatment. Churchill Livingstone; 1998:1101-1114.
    1. Barbet J, Bardiès M, Bourgeois M, et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol. 2012;907:681-697.
    1. Kaminski MS, Estes J, Zasadny KR, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259-1266.
    1. Leahy MF, Turner JH. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood. 2011;117:45-52.
    1. Grillo-López AJ. Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther. 2002;2(5):485-493.

MeSH terms

Substances

LinkOut - more resources